Vis enkel innførsel

dc.contributor.authorFlatø, Berit
dc.contributor.authorRygg, Marite
dc.contributor.authorNordal, Ellen Berit
dc.contributor.authorRøisland, Mona
dc.contributor.authorØdegård, Hanne Beate
dc.contributor.authorHoftun, Gry Børmark
dc.contributor.authorSongstad, Nils Thomas
dc.contributor.authorConsolaro, Alessandro
dc.contributor.authorBovis, Francesca
dc.contributor.authorRuperto, Nicolino
dc.date.accessioned2019-01-09T14:14:13Z
dc.date.available2019-01-09T14:14:13Z
dc.date.created2018-06-21T15:17:12Z
dc.date.issued2018
dc.identifier.citationRheumatology International. 2018, 38 291-298.nb_NO
dc.identifier.issn0172-8172
dc.identifier.urihttp://hdl.handle.net/11250/2580031
dc.description.abstractThe Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Norwegian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic and clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and discriminant validity). A total of 301 JIA patients (3.3% systemic, 41.2% oligoarticular, 25.9% RF negative polyarthritis, and 29.6% other categories) and 74 healthy children were enrolled in three centres. The JAMAR components discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Norwegian version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice and clinical research.nb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Verlagnb_NO
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleThe Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)nb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumber291-298nb_NO
dc.source.volume38nb_NO
dc.source.journalRheumatology Internationalnb_NO
dc.identifier.doi10.1007/s00296-018-3963-y
dc.identifier.cristin1592995
dc.description.localcode© The Author(s) 2018 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal